Home > Rheumatology > EULAR 2020 > Psoriatic Arthritis > Upadacitinib provides fast onset of improvement in psoriatic arthritis

Upadacitinib provides fast onset of improvement in psoriatic arthritis

Results from the double-blind, randomised-controlled, phase 3 trial SELECT-PsA-1 showed that psoriatic arthritis patients with an inadequate response to ≥1 non-biologic disease-modifying anti-rheumatic drug (non-bDMARD) experienced improvement in musculoskeletal symptoms, psoriasis, physical function, pain, and fatigue and inhibited radiographic progression when treated with upadacitinib. These improvements were seen by week 2, and no new safety signals emerged [1].

Upadacitinib, an oral, reversible, Janus kinase (JAK) inhibitor approved for the treatment of rheumatoid arthritis, is currently under evaluation for treatment of psoriatic arthritis. The SELECT-PsA-1 study, presented by Prof. Iain McInnes (University of Glasgow, Scotland), assessed the efficacy and safety of upadacitinib compared with placebo and adalimumab in patients with psoriatic arthritis and prior inadequate response or intole...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on